...bodies next year to assess a path forward. Boehringer, Epizyme terminate epigenetic dealBoehringer Ingelheim GmbH and Epizyme Inc....

...Rock Ventures, where he was an entrepreneur in residence, and previously was SVP of research at Epizyme Inc....

...in combination with anti-PD-1 therapies in patients who have failed to respond to immune checkpoint therapy.Epizyme Inc....

...to Tazverik tazemetostat from Epizyme Inc. (NASDAQ:EPZM) to treat third-line relapsed or refractory follicular lymphoma. An Epizyme...
...Programmed cell death 1 BioCentury Staff Crysvita (burosumab-twza , KRN23, UX023) Tazverik, tazemetostat (E7438, EPZ-6438) Plenity, Gelesis100 (attiva) Ultragenyx Pharmaceutical Inc. Epizyme Inc. Sarepta...

...the wake of its first FDA approval, for Tazverik tazemetostat to treat epitheliod sarcoma (see "Epizyme...
...created position. Baliga was VP of discovery biology at IGM Biosciences Inc. (NASDAQ:IGMS). Robin Sawka, BioCentury Staff Epizyme Inc. ADC...

...had over 3,000 employees. Mott is chairman of Adaptimmune Therapeutics plc (NASDAQ:ADAP), Ardelyx Inc. (NASDAQ:ARDX), Epizyme Inc....

...first approved drug in the indication. A few days later, it approved Tazverik tazemetostat from Epizyme Inc....

...Despite multiple setbacks over the years, Epizyme now has an approved drug on which to hang...
...month, the agency’s Oncologic Drugs Advisory Committee voted 11-0 to recommend approval of the drug. Epizyme Inc....
...in U.S. clinical trials (see “FDA Places Hold on Epizyme’s Tazemetostat” ). In August 2018, Epizyme...

...cancer; and 11-0 for tazemetostat from Epizyme Inc. (NASDAQ:EPZM) for epithelioid sarcoma. Shortly after the vote, Epizyme...

...applications for luspatercept from Celgene Corp. (NASDAQ:CELG) to treat myelodysplastic syndromes and for tazemetostat from Epizyme Inc....